Delving into the Latest Updates on 华中科技大学医院 with Synapse

概览

疾病领域	数量

神经系统疾病	1

排名前五的药物类型	数量

小分子化药	1

关联

1

项与华中科技大学医院相关的药物

Zinc Sulfate Hydrate

硫酸锌

靶点-

作用机制-

在研机构

北京汇诚瑞祥医药技术有限公司 [+3]

原研机构

Abraxis Pharmaceutical Products

在研适应症

膳食补充剂 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1987-05-05

6

项与华中科技大学医院相关的临床试验

ChiCTR2400087734 / SuspendedIIT

Efficacy and safety of optimized post-cyclophosphamide preconditioning regimen (PTCy regimen) for haploid allogenic hematopoietic stem cell transplantation in patients with severe aplastic anemia

开始日期2024-08-10

申办/合作机构

华中科技大学医院

ChiCTR2300079267 / Suspended临床2/3期IIT

A Single-Arm, Multi-Centre Phase II/III Study to Evaluate the Efficacy, Safety, Pharmacokinetic, and Immunogenicity of KJ103 for Desensitisation Therapy in Highly Sensitised Kidney Transplant Patients.

开始日期2024-01-01

申办/合作机构

华中科技大学医院

NCT05686863 / CompletedN/AIIT

Sedative Effect and Safety of Remiazolam Combined With Low-dose Esketamine in Painless Bidirectional Endoscopy in Children

To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.

开始日期2023-01-18

申办/合作机构

华中科技大学医院

100 项与华中科技大学医院相关的临床结果

登录后查看更多信息

0 项与华中科技大学医院相关的专利（医药）

登录后查看更多信息

16

项与华中科技大学医院相关的文献（医药）

2023-05-16·Proceedings of the National Academy of Sciences of the United States of America1区 · 综合性期刊

A large conserved family of small-molecule carboxyl methyltransferases identified from microorganisms.

1区 · 综合性期刊

Article

作者: Hu, Zhiwei ; Deng, Zixin ; Huang, Xiaowei ; Zhou, Linjun ; Lin, Zhi ; Qu, Xudong ; Liu, Benben

Small-molecule carboxyl methyltransferases (CbMTs) constitute a small proportion of the reported methyltransferases, but they have received extensive attention due to their important physiological functions. Most of the small-molecule CbMTs isolated to date originate from plants and are members of the SABATH family. In this study, we identified a type of CbMT (OPCMT) from a group of Mycobacteria, which has a distinct catalytic mechanism from the SABATH methyltransferases. The enzyme contains a large hydrophobic substrate-binding pocket (~400 Å³) and utilizes two conserved residues, Thr20 and Try194, to retain the substrate in a favorable orientation for catalytic transmethylation. The OPCMT_like MTs have a broad substrate scope and can accept diverse carboxylic acids enabling efficient production of methyl esters. They are widely (more than 10,000) distributed in microorganisms, including several well-known pathogens, whereas no related genes are found in humans. In vivo experiments implied that the OPCMT_like MTs was indispensable for M. neoaurum, suggesting that these proteins have important physiological functions.

2023-01-01·Frontiers in oncology

Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study.

作者: Li, Shuang ; Wang, Mingguang ; Liu, Chuan ; Chen, Shubo ; Zhang, Yewei ; Huang, Anliang ; Li, Jinlong ; Liu, Dengxiang ; Yu, Peng ; Zheng, Tianlei ; Wang, Jitao ; Geng, Shi ; Liao, Yong ; Zhang, Zhanguo ; Miao, Hongrui ; Zhang, Biao ; Shang, Dong ; Huang, Yifei ; Liu, Yanna ; Liu, Chengyu ; Qi, Xiaolong ; Liu, Shanghao

[This corrects the article DOI: 10.3389/fonc.2022.986867.].

2020-11-14·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].

Article

作者: Wu, B Y ; Shen, J P ; Zheng, Z J ; Chang, H ; Yang, W R ; Hu, P ; Fei, Y ; Meng, F K ; Han, B ; Wang, Y Q ; Zhang, P ; Ding, X Q ; Ji, D X ; Li, Y M ; Zhang, F K

目的： 评估艾曲泊帕联合免疫抑制治疗（IST）在中国再生障碍性贫血（AA）患者中的疗效及安全性。 方法： 调查分析2015年4月至2019年5月来自中国14个血液病治疗中心、连续应用艾曲泊帕治疗至少3个月的输血依赖非重型和重型AA患者临床资料。 结果： 纳入19例IST初治及37例IST难治性AA患者，中位艾曲泊帕治疗时间为7（3~31）个月，中位艾曲泊帕最大稳定使用剂量为75（50~150）mg/d。10例应用艾曲泊帕联合标准IST一线治疗的SAA患者3个月血液学反应（HR）率为60%，完全HR（CR）率为30%；9例艾曲泊帕联合环孢素A（CsA）一线治疗SAA患者后3个月HR率为89%，CR率为44%。19例患者应用艾曲泊帕联合IST一线治疗，至调查随访时HR率为79%，CR率为52.6%。19例CsA±雄激素治疗无效的AA患者，艾曲泊帕开始治疗后3个月HR率为57.9%（11/19），最佳HR率为68.4%；标准IST治疗无效的难治性AA，艾曲泊帕治疗最佳HR率为44%。51%患者应用艾曲泊帕发生不同严重程度的不良反应，以胃肠道不适最为常见。 结论： 艾曲泊帕治疗可加快HR的获得，改善HR质量；残存造血细胞较多的AA患者或可采用非抗胸腺细胞球蛋白免疫抑制联合艾曲泊帕治疗；艾曲泊帕可作为CsA±雄激素治疗无效AA的补救治疗；艾曲泊帕不良反应轻微，多可耐受。.

100 项与华中科技大学医院相关的药物交易

登录后查看更多信息

100 项与华中科技大学医院相关的转化医学

登录后查看更多信息